

Estimate change	↓
TP change	↔
Rating change	↔

Bloomberg	SRF IN
Equity Shares (m)	296
M.Cap.(INRb)/(USDb)	666.4 / 7.9
52-Week Range (INR)	2697 / 2081
1, 6, 12 Rel. Per (%)	-2/-23/-23
12M Avg Val (INR M)	1377

Financials & Valuations (INR b)

Y/E Mar	2025E	2026E	2027E
Sales	146.2	173.2	199.3
EBITDA	26.6	37.0	46.3
PAT	12.0	20.0	26.4
EBITDA (%)	18.2	21.4	23.2
EPS (INR)	40.5	67.4	88.9
EPS Gr. (%)	(14.7)	66.4	32.0
BV/Sh. (INR)	410	460	532

Ratios

Net D/E	0.4	0.4	0.3
RoE (%)	10.2	15.5	17.9
RoCE (%)	8.7	12.1	14.0
Payout (%)	38.3	25.2	19.1

Valuations

P/E (x)	55.2	33.2	25.1
EV/EBITDA (x)	26.7	19.3	15.5
Div Yield (%)	0.7	0.8	0.8
FCF Yield (%)	0.8	0.3	1.0

Shareholding Pattern (%)

As On	Sep-24	Jun-24	Sep-23
Promoter	50.3	50.3	50.5
DII	17.8	16.6	14.2
FII	18.3	18.7	19.8
Others	13.7	14.4	15.6

Note: FII includes depository receipts

CMP: INR2,248 TP: INR2,080 (-7%) Neutral

Weakness in the Chemicals business hampers performance

Operating performance below estimates

- SRF posted weak performance in 2QFY25, with a material decline in operating profitability (EBIT down 22% YoY), due to the continuous weakness in the Chemicals business (EBIT dipped 29% YoY). The Technical Textiles business also witnessed subdued performance (EBIT down 5% YoY), which was offset by a relatively healthier performance in the Packaging Film business (EBIT grew 7% YoY).
- The overall macro scenario remains uncertain for the Chemicals business (74% EBIT mix in FY24); however, the management is expecting some recovery in 3Q which is likely to further accelerate in 4QFY25, led by a healthy order book in specialty chemicals and ramp-up of export/domestic volumes in the Fluorochemicals business.
- Factoring in the weak macro scenario and uncertain near-term outlook in the Chemicals business, we cut our FY25/FY26 EBITDA estimates by 13%/7%. We value the stock on an SoTP basis to arrive at our TP of INR2,080. **Reiterate Neutral.**

Operating leverage and pricing pressure hurt margin

- SRF reported an overall revenue of INR34.2b (est. of INR35.8b) in 2QFY25, up ~8% YoY. EBITDA margins contracted 390bp YoY to 16.4% (est. of 18.2%). EBITDA stood at INR5.6b (est. of INR6.5b), down 13% YoY. Adj. PAT declined 30% YoY to INR2.2b (est. of INR3.1b).
- Chemicals'** revenue (40%/59% of total sales/EBIT in 2QFY25) declined 5% YoY to INR13.6b, while EBIT declined 29% YoY to INR2.5b. EBIT margin contracted 630bp YoY to 18.1%. The Specialty Chemicals business experienced traction on certain new products, while volumes of some key products witnessed a lower offtake. The Fluorochemicals business witnessed volume growth in the domestic market. Margins were under pressure due to a decline in export realizations.
- Packaging Film's** revenue (41%/20% of total sales/EBIT in 2QFY25) grew 27% YoY to INR14.2b, while EBIT grew 7% YoY to INR828m. Margin contracted 110bp YoY to 5.8%. The BOPET Film business witnessed improved margin in India, while the Thailand business continued to be affected by the Chinese dumping.
- Technical Textiles'** revenue (16%/17% of total sales/EBIT in 2QFY25) grew 6% YoY to INR5.3b. EBIT declined 5% YoY to INR713m. EBIT margin contracted 150bp YoY to 13.3%. The business performed well owing to the higher sales volume of its flagship Nylon Tyre Cord Fabric (NTCF) and healthy demand for its Polyester Yarn segment. However, the Belting Fabrics segment witnessed low demand and margins, impacting the overall performance.
- For 1HFY25, revenue grew 6% YoY to INR68.9b while EBITDA/adj. PAT declined 13%/30% YoY to INR11.8b/INR5b. Based on our estimates, the implied revenue/EBITDA growth for 2HFY25 is 17%/14% YoY, led by a recovery in the Chemicals business.

Sumant Kumar - Research Analyst (Sumant.Kumar@MotilalOswal.com)

Research Analyst: Meet Jain (Meet.Jain@MotilalOswal.com) / **Omkar Shintre** (Omkar.Shintre@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- The **Chemicals business** is facing headwinds but is likely to witness a revival in 2HFY25. The company is not witnessing demand contraction for any product, but inventory rationalization is leading to lower offtakes. The management has not provided any growth guidance due to the current volatile macro scenario.
- **Packaging business:** The BOPET Film segment witnessed healthy domestic performance, while the Thailand business was hampered due to stiff Chinese competition and logistics issues. The company is expecting recovery in 2HFY25, led by the proposed imposition of anti-dumping duty by the US on Chinese imports.
- **Capex:** SRF has incurred a cash capex of ~INR6.5b in 1HFY25. It expects to incur a total capex of ~INR16-18b in FY25. This is much lower than the initial expectation, but the company will announce capex as and when the situation improves.

Valuation and view

- The Chemicals business (Fluorochemicals and specialty chemicals) is expected to witness some recovery in 2HFY25, led by a strong order book in the specialty business and ramp-up of export volumes coupled with gradual growth in PTFE within the Fluorochemicals business. The packaging business is likely to remain under pressure in the medium term, while the Technical Textiles business is likely to continue the current growth momentum.
- Factoring in the weak macro scenario and uncertain near-term outlook in the chemicals business, we cut our FY25/FY26 EBITDA estimates by 13%/7%. We value the stock on an SoTP-basis to arrive at our TP of INR2,080. **Reiterate Neutral.**

Consolidated - Quarterly Earning Model

(INR m)


Y/E March	FY24				FY25E				FY24	FY25E	FY25E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2Q	%
Net Sales	33,384	31,774	30,530	35,697	34,641	34,243	35,555	41,759	1,31,385	1,46,198	35,841	-4
YoY Change (%)	-14.3	-14.8	-12.0	-5.5	3.8	7.8	16.5	17.0	-11.6	11.3	12.8	
Total Expenditure	26,184	25,320	24,691	28,581	28,435	28,637	29,196	33,363	1,04,777	1,19,630	29,315	
EBITDA	7,200	6,453	5,839	7,116	6,207	5,606	6,360	8,396	26,608	26,568	6,526	-14
Margins (%)	21.6	20.3	19.1	19.9	17.9	16.4	17.9	20.1	20.3	18.2	18.2	
Depreciation	1,566	1,612	1,689	1,859	1,882	1,939	1,950	2,180	6,726	7,951	1,950	
Interest	656	793	674	900	965	938	920	900	3,023	3,723	750	
Other Income	118	291	188	234	253	333	300	310	830	1,196	280	
PBT before EO Expense	5,095	4,339	3,664	4,591	3,612	3,063	3,790	5,626	17,689	16,090	4,106	
Extra-Ord Expense & DO	237	191	181	158	172	226	0	0	767	398	0	
PBT	4,858	4,148	3,483	4,433	3,440	2,837	3,790	5,626	16,922	15,692	4,106	
Tax	1,265	1,140	949	211	918	822	928	1,379	3,565	4,047	1,006	
Rate (%)	24.8	26.3	25.9	4.6	25.4	26.9	24.5	24.5	20.2	25.2	24.5	
Reported PAT	3,593	3,008	2,534	4,222	2,522	2,014	2,861	4,247	13,357	11,645	3,100	
Adj PAT	3,830	3,199	2,715	4,380	2,695	2,240	2,861	4,247	14,124	12,043	3,100	-28
YoY Change (%)	-39.5	-38.1	-48.4	-25.8	-29.6	-30.0	5.4	-3.0	-37.7	-14.7	-3	
Margins (%)	11.5	10.1	8.9	12.3	7.8	6.5	8.0	10.2	10.8	8.2	8.7	

Key Performance Indicators

Y/E March	FY24				FY25E				FY24	FY25E	FY25E
Consolidated	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE
Segment Revenue (INR m)											
Technical Textile	4,647	5,062	4,584	4,689	5,253	5,355	5,134	5,298	18,980	21,040	5,568
Chemicals	16,605	14,263	13,941	18,161	14,820	13,578	16,032	21,793	62,970	66,223	14,834
Packaging Film	10,948	11,215	10,907	11,824	13,363	14,206	13,197	13,479	44,893	54,245	14,019
Others	1,187	1,269	1,136	1,062	1,262	1,128	1,192	1,189	4,653	4,771	1,421
Segment Revenue Growth (%)											
Technical Textile	-18.6	8.6	7.6	8.9	13.1	5.8	12.0	13.0	0.2	10.9	10.0
Chemicals	-3.6	-22.1	-20.6	-13.6	-10.8	-4.8	15.0	20.0	-15.0	5.2	4.0
Packaging Film	-26.8	-15.7	-9.3	2.5	22.1	26.7	21.0	14.0	-13.4	20.8	25.0
Other	12.4	26.4	23.0	12.6	6.3	-11.1	5.0	12.0	18.5	2.5	12.0
Segment Results (INR m)											
Technical Textile	607	750	688	698	677	713	744	821	2,742	2,956	779
Chemicals	4,601	3,478	3,219	4,977	3,064	2,461	3,367	5,012	16,274	13,905	3,189
Packaging Film	513	773	449	331	868	828	858	944	2,065	3,497	953
Others	232	331	212	156	236	172	191	190	930	789	355
Segment EBIT Margins (%)											
Technical Textile	13.1	14.8	15.0	14.9	12.9	13.3	14.5	15.5	14.4	14.0	14.0
Chemicals	27.7	24.4	23.1	27.4	20.7	18.1	21.0	23.0	25.8	21.0	21.5
Packaging Film	4.7	6.9	4.1	2.8	6.5	5.8	6.5	7.0	4.6	6.4	6.8
Others	19.5	26.1	18.7	14.7	18.7	15.2	16.0	16.0	20.0	16.5	25.0
Cost Break-up											
RM Cost (% of sales)	50.9	51.0	50.9	51.4	52.7	53.6	52.7	52.4	51.1	52.8	47.3
Staff Cost (% of sales)	6.5	7.1	8.0	6.9	7.3	7.4	7.3	6.2	7.1	7.0	7.3
Power and Fuel Cost (% of sales)	10.6	10.8	10.5	9.2	9.9	10.1	10.0	9.7	10.2	9.9	12.2
Other Cost (% of sales)	10.4	10.7	11.5	12.6	12.2	12.6	12.2	11.6	11.3	12.1	9.9
Gross Margins (%)	49.1	49.0	49.1	48.6	47.3	46.4	47.3	47.6	48.9	47.2	52.7
EBITDA Margins (%)	21.6	20.3	19.1	19.9	17.9	16.4	17.9	20.1	20.3	18.2	18.2
EBIT Margins (%)	16.9	15.2	13.6	14.7	12.5	10.7	12.4	14.9	15.1	12.7	13.2


Key Exhibits

Exhibit 1: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 3: Consolidated adjusted PAT trend




Source: Company, MOFSL

Exhibit 4: Revenue mix trend




Source: Company, MOFSL


Exhibit 5: EBIT mix trend




Source: Company, MOFSL

Exhibit 6: Revenue trend in the Chemicals business


Source: Company, MOFSL

Exhibit 7: EBIT trend in the Chemicals business


Source: Company, MOFSL

Exhibit 8: Revenue trend in the Packaging Film business


Source: Company, MOFSL

Exhibit 9: EBIT trend in the Packaging Film business

Source: Company, MOFSL

Exhibit 10: Revenue trend in the Technical Textiles business

Source: Company, MOFSL

Exhibit 11: EBIT trend in the Technical Textiles business

Source: Company, MOFSL



Key highlights from the management commentary

Chemicals business:

- **The Specialty Chemicals business** continued to face headwinds during the quarter. The overall Specialty Chemicals business was down ~4-4.5% in 1HFY25.
- The company is witnessing decent volumes while pricing is improving; hence, the management expects recovery in margins by 4Q.
- Currently, the company has a strong order book at hand, but customers are delaying product registration amid global pressure. The company's ongoing discussion with customers is positive.
- The company has commercialized 3 new products each in the agro and pharma segment in 1HFY25.
- Domestic sales account for ~25-30% of revenues while international sales account for the remaining. The company expects this trend to continue going forward.
- The company is currently working on 7 AIs, out of this ~3 will start to witness traction in FY25 itself.
- SRF has spent ~INR18b on initiating several new plants in this segment.
- **The Fluorochemicals segment** witnessed healthy performance in the domestic market with an increase in overall volumes. However, reduced export realizations put pressure on margins.
- Developed markets such as the US are witnessing lower volumes. However, it is in line with the expectation. The company expects this trend to continue going forward.
- The Indian and Middle Eastern markets will continue to make up for the volumes lost from some of the developed geographies.
- The company witnessed an increased market share in both the RAC and MAC segments.
- HFC prices are under pressure in the US market but volumes in the domestic market were strong. The company expects these trends to continue going forward.
- The company expects gradual growth in PTFE, led by customer approvals.
- It expects pricing pressure in Chloromethane to sustain. Margins have started to expand from 2Q onwards. The company is currently preparing for the commercial phase of the products.
- **The overall Chemicals business** is facing headwinds but is expected to witness recovery from 2HFY25. The company is not witnessing demand contraction for any products. However, customers are rationalizing inventory, factoring in the pricing pressure and global interest rate cycle.
- The company expects better volumes from 3QFY25 onwards, while the offtake is expected to further accelerate in 4Q with the company anticipating major recovery and dispatched from 4QFY25.
- The company has not provided any growth guidance due to the current volatile macro scenario.

Packaging film business

- The BOPET Film business performed well in India owing to better pricing and margins in 2QFY25. However, the performance in Thailand was impacted due to stiff Chinese competition. Further, the significant surge in ocean freights and container availability negatively impacted exports from Thailand.
- The company is expecting this business to ramp up in 2HFY25, led by the anti-dumping duty by the US on Chinese imports.
- The BOPP Film business is stable and performing well. The company is adding more value-added products in this segment.
- It is witnessing better domestic volumes from the aluminum foil product. Sampling for the export volumes has increased and the company is expecting export orders soon. It is anticipating strong performance from this product from 4Q onwards.

Technical textiles business:

- The Technical Textiles business performed well owing to the higher sales volume of Nylon Tyre Cord Fabric and healthy demand for its Polyester Yarn segment. The Belting Fabrics segment witnessed low demand and margins, which impacted the overall performance.
- The company continued to focus on enhancing high-end VAP sales in Belting Fabrics, with entry into a new geography and commercialization of 8 new VAPs in 1HFY25.
- Going forward, the demand for NTCF and PIY is expected to remain strong, while the demand for belting fabrics may stay flat. However, aggressive import prices of belting fabrics from China may continue to impact margins.

Capex:

- The company has incurred a cash capex of ~INR6.5b in 1HFY25. It expects to incur a total capex of ~INR16-18b in FY25. This is much lower than the initial expectation, but the company will announce capex as and when the situation improves.
- The Board has approved a project to establish production facilities for fourth-generation refrigerants, which have a notably lower Global Warming Potential (GWP) and carbon footprint, at an estimated cost of INR11b. The project is anticipated to be completed in about 30 months.
- The company will establish a ~60KMT manufacturing facility for the BOPP-BOPE film (including metalizer) in Indore, India for the projected cost of INR4.45b, which is expected to be operational in approximately 25 months.

Valuation and view

- The Chemicals business (Fluorochemicals and specialty chemicals) is expected to witness some recovery in 2HFY25, led by a strong order book in the specialty business and ramp-up of export volumes within the Fluorochemicals business. The Packaging business is likely to remain under pressure in the medium term, while the Technical Textiles business is likely to maintain the current growth momentum.
- Factoring in the weak macro scenario and uncertain near-term outlook in the Chemicals business, we cut our FY25/FY26 EBITDA estimates by 13%/7%. We value the stock on an SoTP-basis to arrive at our TP of INR2,080. Reiterate **Neutral**.

Exhibit 12: Valuation methodology

EV/EBITDA	FY26 EBITDA (INRm)	Multiple (x)	EV (INRm)
Technical Textiles	4,448	11	50,713
Chemicals	27,108	19	5,27,520
Packaging Films	7,665	11	87,378
Others	1,199	6	7,195
Total EV			6,72,806
Less: Debt			56,202
Less: Minority Interest			-
Add: Cash & Cash Equivalents			2,049
Target Mcap (INR m)			6,18,653
Outstanding Share (m)			297.4
Target Price (INR)			2,080

Source: MOFSL

Exhibit 13: Revisions to our estimates

Earnings Change (INR m)	Old		New		Change (%)	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY25E
Revenue	1,52,606	1,78,140	1,46,198	1,73,182	-4	-3
EBITDA	30,409	39,649	26,568	37,048	-13	-7
Adj. PAT	15,209	21,951	12,043	20,035	-21	-9

Source: MOFSL

Financials and valuations

Consolidated - Income Statement									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Total Income from Operations	70,996	72,094	84,000	1,24,337	1,48,703	1,31,385	1,46,198	1,73,182	1,99,311
Cost of Materials Consumed	39,671	36,870	40,189	60,669	73,935	67,088	77,234	89,211	1,01,167
Personnel Expenses	4,608	5,419	6,214	7,800	8,138	9,350	10,214	11,257	12,557
Other Expenses	13,508	15,221	16,264	24,835	30,297	28,339	32,182	35,667	39,288
Total Expenditure	57,787	57,510	62,667	93,305	1,12,371	1,04,777	1,19,630	1,36,134	1,53,012
EBITDA	13,209	14,584	21,333	31,032	36,332	26,608	26,568	37,048	46,299
Margin (%)	18.6	20.2	25.4	25.0	24.4	20.3	18.2	21.4	23.2
Depreciation	3,582	3,886	4,531	5,172	5,753	6,726	7,951	8,965	10,133
EBIT	9,627	10,698	16,803	25,860	30,579	19,882	18,617	28,083	36,166
Int. and Finance Charges	1,984	2,007	1,340	1,159	2,048	3,023	3,723	2,981	2,860
Other Income	280	491	545	428	749	830	1,196	1,435	1,722
PBT bef. EO Exp.	7,923	9,182	16,008	25,128	29,280	17,689	16,090	26,537	35,028
EO Items	262	997	116	727	-1,040	-767	-398	0	0
PBT after EO Exp.	8,185	10,179	16,123	25,856	28,240	16,922	15,692	26,537	35,028
Current Tax	1,769	265	4,154	7,139	6,617	3,565	4,047	6,502	8,583
Deferred Tax	0	-277	-10	-173	0	0	0	0	0
Tax Rate (%)	21.6	-0.1	25.7	26.9	23.4	21.1	25.8	24.5	24.5
Less: Minority Interest	0	0	0	0	0	0	0	0	0
Reported PAT	6,416	10,191	11,979	18,889	21,623	13,357	11,645	20,035	26,445
Adjusted PAT	6,155	9,194	11,864	18,162	22,663	14,124	12,043	20,035	26,445
Change (%)	48.2	49.4	29.0	53.1	24.8	-37.7	-14.7	66.4	32.0
Margin (%)	8.7	12.8	14.1	14.6	15.2	10.8	8.2	11.6	13.3

Consolidated - Balance Sheet									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity Share Capital	575	585	603	2,974	2,974	2,974	2,974	2,974	2,974
Preference Capital	0	0	0	0	0	0	0	0	0
Total Reserves	40,718	48,748	67,962	82,679	1,00,296	1,11,816	1,18,999	1,33,977	1,55,366
Net Worth	41,293	49,333	68,564	85,654	1,03,271	1,14,790	1,21,973	1,36,952	1,58,341
Minority Interest	0	0	0	0	0	0	0	0	0
Deferred Liabilities	3,420	1,755	3,862	6,775	8,092	9,387	9,387	9,387	9,387
Total Loans	37,302	40,468	33,950	35,394	43,541	49,202	52,202	56,202	58,202
Capital Employed	82,014	91,556	1,06,376	1,27,822	1,54,903	1,73,380	1,83,563	2,02,541	2,25,930
Gross Block	68,322	76,934	96,167	1,06,943	1,28,622	1,67,373	1,93,373	2,13,373	2,46,373
Less: Accum. Deprn.	12,269	15,540	20,071	25,243	30,997	37,723	45,674	54,638	64,771
Net Fixed Assets	56,053	61,394	76,096	81,699	97,626	1,29,650	1,47,699	1,58,734	1,81,601
Goodwill on Consolidation	41	6	6	0	0	0	0	0	0
Capital WIP	7,536	13,933	7,723	16,716	24,055	8,053	53	7,053	2,053
Current Investments	1,005	1,985	4,125	3,167	4,901	4,056	4,056	4,056	4,056
Total Investments	1,006	2,027	4,167	3,209	4,942	5,267	5,267	5,267	5,267
Curr. Assets, Loans & Adv.	34,243	31,265	41,121	56,025	60,735	61,574	64,930	69,377	79,550
Inventory	12,247	12,012	14,658	21,385	22,743	23,265	24,334	26,397	29,934
Account Receivables	10,288	8,911	12,746	17,925	17,856	19,428	19,226	21,351	24,573
Cash and Bank Balance	1,989	1,255	2,820	4,594	6,165	4,075	4,344	2,049	2,526
Loans and Advances	9,719	9,088	10,898	12,123	13,972	14,805	17,026	19,580	22,517
Curr. Liability & Prov.	16,865	17,211	22,918	29,944	32,642	31,440	34,662	38,166	42,817
Account Payables	13,824	11,117	15,852	20,964	22,313	21,978	24,334	26,885	30,489
Other Current Liabilities	2,600	5,653	6,544	8,391	9,642	8,660	9,526	10,479	11,527
Provisions	441	442	522	590	687	802	802	802	802
Net Current Assets	17,378	14,054	18,203	26,081	28,093	30,134	30,268	31,211	36,733
Deferred Tax assets	0	143	181	116	187	276	276	276	276
Misc Expenditure	0	0	0	0	0	0	0	0	0
Appl. of Funds	82,014	91,556	1,06,376	1,27,822	1,54,903	1,73,380	1,83,563	2,02,541	2,25,930

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Basic (INR)									
EPS	20.7	30.9	39.9	61.1	76.2	47.5	40.5	67.4	88.9
Cash EPS	32.7	44.0	55.1	78.5	95.5	70.1	67.2	97.5	123.0
BV/Share	138.8	165.9	230.5	288.0	347.2	385.9	410.1	460.4	532.3
DPS	3.9	2.8	4.9	16.8	7.2	7.2	15.0	17.0	17.0
Payout (%)	20.8	9.6	12.1	26.4	9.9	16.0	38.3	25.2	19.1
Valuation (x)									
P/E	108.0	72.3	56.0	36.6	29.3	47.0	55.2	33.2	25.1
Cash P/E	68.2	50.8	40.5	28.5	23.4	31.9	33.2	22.9	18.2
P/BV	16.1	13.5	9.7	7.8	6.4	5.8	5.4	4.9	4.2
EV/Sales	9.8	9.7	8.2	5.6	4.7	5.4	4.8	4.1	3.6
EV/EBITDA	52.9	48.1	32.4	22.3	19.2	26.5	26.7	19.3	15.5
Dividend Yield (%)	0.2	0.1	0.2	0.7	0.3	0.3	0.7	0.8	0.8
FCF Per Share	-5.3	-2.3	19.1	9.7	0.0	-6.1	18.3	5.9	21.5
Return Ratios (%)									
RoE	16.0	20.3	20.1	23.6	24.0	13.0	10.2	15.5	17.9
RoCE	10.7	13.3	13.4	17.2	17.9	10.5	8.7	12.1	14.0
RoIC	18.0	15.3	26.3	34.2	34.7	18.2	15.1	20.3	23.3
Working Capital Ratios									
Accum. Dep/Gross Block (x)	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover (x)	1.0	0.9	0.9	1.2	1.2	0.8	0.8	0.8	0.8
Asset Turnover (x)	0.9	0.8	0.8	1.0	1.0	0.8	0.8	0.9	0.9
Inventory (Days)	113	119	133	129	112	127	115	108	108
Debtor (Days)	53	45	55	53	44	54	48	45	45
Creditor (Days)	127	110	144	126	110	120	115	110	110
Working Cap. Turnover (Days)	79	65	67	63	54	72	65	61	63
Leverage Ratio (x)									
Current Ratio	2.0	1.8	1.8	1.9	1.9	2.0	1.9	1.8	1.9
Interest Cover Ratio	5	5	13	22	15	7	5	9	13
Debt/Equity	0.9	0.8	0.5	0.4	0.4	0.4	0.4	0.4	0.4

Consolidated - Cash Flow Statement

(INRM)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
OP/(Loss) before Tax	8,269	10,706	16,099	25,856	28,240	16,922	15,692	26,537	35,028
Depreciation	3,669	3,929	4,531	5,172	5,753	6,726	7,951	8,965	10,133
Interest & Finance Charges	2,016	2,016	1,340	1,159	2,048	3,023	3,723	2,981	2,860
Direct Taxes Paid	-1,502	-1,427	-2,553	-4,016	-6,617	-3,565	-4,047	-6,502	-8,583
(Inc)/Dec in WC	-3,165	-239	-1,236	-6,645	-408	-2,168	134	-3,238	-5,045
CF from Operations	9,286	14,984	18,181	21,527	29,017	20,938	23,453	28,743	34,394
Others	-330	-1,940	-464	-469	0	0	0	0	0
CF from Operating incl EO	8,956	13,044	17,717	21,057	29,017	20,938	23,453	28,743	34,394
(inc)/dec in FA	-10,526	-13,730	-12,047	-18,171	-29,019	-22,748	-18,000	-27,000	-28,000
Free Cash Flow	-1,570	-685	5,670	2,886	-2	-1,810	5,453	1,743	6,394
(Pur)/Sale of Investments	332	-886	-1,886	1,028	-1,733	-325	0	0	0
Others	53	2,813	-1,064	1,265	1,138	800	0	0	0
CF from Investments	-10,142	-11,803	-14,997	-15,877	-29,614	-22,273	-18,000	-27,000	-28,000
Issue of Shares	1	0	7,500	2	0	0	0	0	0
Inc/(Dec) in Debt	2,677	3,205	-6,856	622	8,147	5,662	3,000	4,000	2,000
Interest Paid	-2,241	-2,040	-1,574	-1,173	-2,048	-3,023	-3,723	-2,981	-2,860
Dividend Paid	-836	-803	-1,408	-2,117	-2,142	-2,142	-4,462	-5,056	-5,056
Others	2,606	-2,337	1,182	-741	-1,789	-1,252	0	0	0
CF from Fin. Activity	2,207	-1,975	-1,155	-3,406	2,168	-754	-5,185	-4,038	-5,917
Inc/Dec of Cash	1,021	-734	1,565	1,774	1,571	-2,089	268	-2,294	477
Opening Balance	967	1,989	1,255	2,820	4,594	6,164	4,075	4,344	2,049
Closing Balance	1,989	1,255	2,820	4,594	6,164	4,075	4,344	2,049	2,526

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.